Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Ying-Shuan E. Lee, Mann-Yan Kuo, Yi-Ting Huang, Yu-Wen Tseng, Yu Jie Lin, Yen His Liu, Shian-Yi Chiou, Li Jung Chen, Y.-Y. Lu, Chih-Hsin Yang, and Pan-Chyr Yang | ||||||||||||
Title | Abstract C270: In vitro and in vivo antitumor activity of DCBCI0901, a potent PI3K/mTORC1/mTORC2 inhibitor. | ||||||||||||
|
|||||||||||||
URL | http://mct.aacrjournals.org/content/12/11_Supplement/C270.short | ||||||||||||
Abstract Text |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DCBCI0901 | mTOR Inhibitor 51 PI3K Inhibitor (Pan) 40 | DCBCI0901 is an inhibitor of PI3K, mTORC1, and mTORC2, which may result in antitumor activity, including inhibition of cell survival, proliferation, and tumor growth (Mol Cancer Ther 2013;12(11 Suppl):Abstract nr C270). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|